卓勝微(300782.SZ):於二季度推出的L-PAMiD是目前業界首次實現全國產供應鏈的系列產品,並且已在部分品牌客户驗證通過
格隆匯11月14日丨卓勝微(300782.SZ)在投資者互動平台表示,卓勝微是目前國內射頻前端領域中業務較為全面,產業鏈佈局最為領先和完整的企業之一。公司產品均為自主研發,部分產品已實現全國產化供應,公司於二季度推出的L-PAMiD是目前業界首次實現全國產供應鏈的系列產品,並且已在部分品牌客户驗證通過。未來,公司將逐步落地射頻“智能質造”資源平台建設,打造具備性能、成本、交付、質量、差異化、效率提升等綜合優勢的產品,專注佈局和投資新的前沿技術,突破工藝技術壁壘,真正對標國際頭部企業,為公司構建新的核心競爭力,為客户提供更全面的附加價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.